Author: Abdur-rahman et al. Summary: Diabetic Macular Edema (DME) and Age-Related Macular Degeneration (AMD) are two significant causes of vision impairment and central vision loss that impose an increasingly high burden on both patients and healthcare systems worldwide. The preferred treatment for DME and AMD patients is the use of anti-vascular endothelial growth factor (VEGF) agents. These agents play a crucial role in triggering angiogenesis, enhancing vascular permeability, disrupting the blood retinal barrier, and inducing inflammatory reactions.1 At present there are three approved VEGF-agents for treatment of AMD and DME: Ranibiziumab, Aflibercept and Brolucizumab. Extensive evidence has demonstrated that the